dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

NorthStar buys IBA electron accelerators for Mo-99 production Will increase production capacity and efficiencies

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Using image-guided nuclear intervention to cut cancer cells off at the pass

by John W. Mitchell , Senior Correspondent
The rapidly developing field of nuclear medicine tracers — or probes — to noninvasively study cancer cells in real time during treatment got an "exciting" boost this week. A research team from Massachusetts General Hospital in Boston and Memorial Sloan Kettering in New York City published findings in the Journal of Nuclear Medicine that may help doctors respond more accurately with supplemental cancer treatments.

"Oftentimes, targeted cancer therapies are combined to kill tumors. One of the ways tumors sometimes avoid being killed is by responding to a therapy to overcome its effects," Umar Mahmood, M.D., Ph.D., a member of the research team, a professor of radiology and director of the Division of Precision Medicine at Harvard Medical School, told HCB News.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



According to Mahmood, the nuclear medicine probes they have developed in combination with PET imaging can help determine the best way to overcome a specific tumor's effort to resist treatment.

"We can image some of the common ways this can happen with several important classes of treatment, and then use that information to give the tumors the most effective second (therapy) punch," said Mahmood.

He likened breast cancer treatment to a chess game with the tumor.

"We have made a move by blocking a signaling node," explained Mahmood. "The cancer cell has responded by increasing a cell surface receptor to overcome this block. Our imaging allows us to make an optimal move to specifically block the type of cell surface receptor the cell increased.”

This monitoring at the cell level is possible with the image-guided probe interventions, specific nuclear tracers that help image tumor biology under PET scans.

The specific clinical findings of the team's study show that imaging of cell surface receptor changes with PET probes specific to epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 3 (HER3). This finding directly addresses an unmet need in cancer therapy decision-making, while avoiding the need for repeat biopsies.

Mahmood said the potential of their research is that a great number of specific cell processes can be imaged noninvasively. A patient benefits from real-time data to help their oncologists optimize their treatment on an individual basis, rather than relying on standing protocols.

He said the team next plans to apply their findings to prostate cancer and then lung cancer.

"It is an exciting time for image-guided interventions," said Mahmood.

Back to HCB News
  Pages: 1

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED